Abstract library

693 results for "aggressive surgery".
#766 Aggressive Surgery for Pancreatic Neuroendocrine Tumors
Introduction: The role of surgery for advanced pancreatic neuroendocrine tumor (pNET) requiring extended resections is not well-defined.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Biomarkers
Presenting Author: Nadia Russolillo
#137 Extensive ""multitasking"" surgery for advanced neuroendocrine tumors is safe and effective
Introduction: Management of advanced NETs is controversial, related to degree of intervention; the pendulum is swinging towards a more aggressive interventional approach. Our Center's philosophy is to offer a systematic, planned multimodality treatment for patients with advanced NETs.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD MICHAIL K Shafir
#497 Metastatic Pancreatic Neuroendocrine Carcinoma: Does Aggressive Surgical Intervention Improve Outcome?
Introduction: Pancreatic neuroendocrine tumors (PNETS) often present late. At diagnosis, 65% of patients have metastases, with median survival of 24 months. The conventional approach is conservative management. Recent evidence has suggested that aggressive treatment leads to better outcomes.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Michael White
Keywords: pancreatic, surgery
#1352 Outcomes of Cytoreductive Surgery for Well-Differentiated Metastatic Neuroendocrine Tumors in the Setting of Extra-Hepatic Metastases
Introduction: Cytoreduction with extra-hepatic disease for neuroendocrine tumors (NET) remains controversial
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Surgical treatment
Presenting Author: Hallet Julie
#83 Surgical treatment of duodenopancreatic neuroendocrine tumors (pNETs) in patients with multiple endocrine neoplasia type 1 (MEN 1): a Dutch consensus statement
Introduction: Duodenopancreatic neuroendocrine tumors (pNETs) in multiple endocrine neoplasia type 1 (MEN 1) are the most important cause of MEN 1-related death. Surgery is the only curative treatment, but controversy exists on the optimal strategy. Recent guidelines on pNETs have limited recommendations specific for MEN 1. Therefore, a Dutch multidisciplinary consensus meeting was organized.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Carolina RC Pieterman
#14 Radioguided surgery in NET: First impression with Ga-68 labeled somatostatin analogues
Introduction: Neuroendocrine tumors (NET) constitute a heterogenous group of neoplasms. The development of Gallium-68-labeled somatostatin analogues, such as DOTA-NOC or DOTA-TOC, PET/CT have dramatically improved the diagnosis of neuroendocrine tumors. Surgery remains the treatment of choice for localized disease as well as metastatic disease. The aims of surgery are: improvement of symptoms, reduction of tumor mass / burden and to give better quality of life to patients. Recurrent laparotomies often lead to multiple adhesions and altered anatomy. So it is increasingly difficult for imaging physicians and surgeons to separate non-malignant from malignant tissue.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Daniel Kaemmerer
#1604 Resection of Liver Metastases in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Carcinomas: A Nordic Multicenter Study
Introduction: Gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC) are generally characterized by synchronous metastases, high aggressiveness and a dismal prognosis. Currently, resection of liver metastases in patients with metastatic GEP-NEC is not recommended. However, the existing data are scarce.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Surgical treatment
Presenting Author: MD Renate Berget Galleberg
#2716 Neuroendocrine Carcinoma of the Upper Urinary Tract: A Case Report
Introduction: There are no dedicated guidelines for treatment of urothelial NEC given disease rarity. An aggressive approach, including neoadjuvant cisplatin-based chemotherapy + nephroureterectomy and adjuvant platinum-based chemotherapy, is recommended.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Dr Roberta Elisa Rossi
#3076 Endometrial Small Cell Neuroendocrine Carcinoma: Case Report and Literature Review
Introduction: Endometrial small-cell neuroendocrine carcinoma (ESCNEC) is extremely rare. It is characterized by early regional and systemic spread leading to rapid development of lymph nodes, pelvic and extrapelvic metastasis and compromising the outcome.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Dr Mohammed Alaeddine Saidi
Authors: Aris H, Ghomari S, ...
#1017 The Natural History of an Apparently Aggressive Gastric Neuroendocrine Neoplasm Type 1
Introduction: Gastric neuroendocrine neoplasm type 1 (GNEN1) is the most common GEP-NETs. GNEN1 has traditionally been considered non-metastatic as compared to the large, solitary GNEN3 that has high malignant potential.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Clinical cases/reports
Presenting Author: Dr Krystallenia Alexandraki
Keywords: GNEN1